Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE2
Total Enrollment
60 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-05-17
Study Completion Date
2028-05-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Chronic non-healing wounds are becoming an increasingly more common problem. Eligible, consenting patients with chronic wounds in the lower extremities, upper extremities or trunk, will either continue to the standard of care or will be randomized to the treatment cohort where antibiotic solution will be injected in the area around the wound. All patients will continue standard wound care as dictated by the wound care clinic. Subjects of both the control and treatment will have approximately 6 study specific visits that may or may not coincide with previously schedule wound care clinic visits. As these specified visits wound size and healing will be documented and patients will complete surveys. The study will conclude for the subject after approximately 6 months. Again, these patients may continue standard wound care but will no longer have study obligations.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Omeza Combination Therapy for the Management and Treatment of Chronic Cutaneous Wounds/Ulcers of Multiple Etiologies
NCT05921292
Non-healing Wound
Non-Healing Ulcer of Skin
COMPLETED
EARLY_PHASE1
MIST Therapy's Effectiveness in Wound Bed Preparation and Role of Bacterial Biofilm in Chronic, Non-healing Wounds
NCT01125735
Chronic Nonhealing Wounds
WITHDRAWN
PHASE4
PRF With Topical Antibiotics or Antiseptics in Chronical Wounds Version 1.4
NCT02652169
Chronic Skin Ulcer
RECRUITING
NA
Investigation of a Novel Wound Gel to Improve Wound Healing in Chronic Wounds
NCT03686904
Wound Infection
COMPLETED
PHASE4
A Retrospective Analysis of Laboratory Testing on Chronic Wound Patients
NCT02142426
Wound Chronic Draining
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Foot ulcers develop in 9.1-26 million people with diabetes annually worldwide. Up to 1% of people in industrialized countries will suffer from a leg ulcer. Numbers of pressure and venous ulcers are rising at rates of 6-7% annually, diabetic ulcers rising at 9%. In the United States, chronic wounds affect 6.5 million patients and over $25 billion dollars are spent annually on chronic wound care. Medicare spending on pressure and arterial ulcers in 2014 was $3696 and $9015 per patient. Diabetic limb complications are more costly than breast cancer.
Attempts to treat chronic wounds have included 1) debridement, 2) specialized dressings, 3) compression bandages, 4) negative pressure devices, 5) topical growth factors and pharmaceuticals, 6) skin grafts and skin substitutes, 7) hyperbaric oxygen therapy and 8) amputation. There is no study that examines the utility of tumescent antibiotic injections (TAI) into a wound. TAI is a relatively simple, cost-effective procedure using known, drugs with a well characterized safety profile, and used in a new way to address this large unmet need.
Our group has published work in this area showing appropriate design, feasibility and safety in a large animal model. The investigators have shown that direct antibiotic delivery through tumescent injections can achieve high antibiotic concentrations directly in skin and soft tissue for sufficient time to kill bacteria. Simultaneously, total antibiotic doses can be kept low, minimizing systemic toxicity. In particular, even antibiotic resistant strains of pathogenic microorganisms may be susceptible due to the high local concentration of antimicrobial agent. Tumescent injections can more effectively deliver antibiotic to compromised body regions with impaired circulation compared to intramuscular or intravenous drug delivery.
Primary Objective
1\. To assess the safety of tumescent antibiotic injections.
Secondary Objectives
1. To evaluate wound size or closure.
2. To evaluate chronic-wound-related pain.
3. To evaluate Quality of Life.
Exploratory Objectives
1. Assess the number of chronic wound-related complications (increased wound sizes, infections, dermatitis).
2. Assess the number of clinical signs of infection in participants.
3. Determine the species of pathogenic bacteria present in wound.
Screening: up to 1 week. Treatment: TAI will take 1 day. Standard wound care will be ongoing until the wound closes, as it would in a wound care center.
Follow-up:
Once weekly (+/-1 week) for 2 weeks, followed by Biweekly (+/-1week) for 4 more weeks. There will also be a 3 month (+/- 2 weeks) and 6 month (+/- 4 weeks) follow up visits. Total duration of participant participation is up to approximately 1 year. Total duration of the study for recruitment and completion of visits is expected to be up to two years.
Attempts to treat chronic wounds have included 1) debridement, 2) specialized dressings, 3) compression bandages, 4) negative pressure devices, 5) topical growth factors and pharmaceuticals, 6) skin grafts and skin substitutes, 7) hyperbaric oxygen therapy and 8) amputation. There is no study that examines the utility of tumescent antibiotic injections (TAI) into a wound. TAI is a relatively simple, cost-effective procedure using known, drugs with a well characterized safety profile, and used in a new way to address this large unmet need.
Our group has published work in this area showing appropriate design, feasibility and safety in a large animal model. The investigators have shown that direct antibiotic delivery through tumescent injections can achieve high antibiotic concentrations directly in skin and soft tissue for sufficient time to kill bacteria. Simultaneously, total antibiotic doses can be kept low, minimizing systemic toxicity. In particular, even antibiotic resistant strains of pathogenic microorganisms may be susceptible due to the high local concentration of antimicrobial agent. Tumescent injections can more effectively deliver antibiotic to compromised body regions with impaired circulation compared to intramuscular or intravenous drug delivery.
Primary Objective
1\. To assess the safety of tumescent antibiotic injections.
Secondary Objectives
1. To evaluate wound size or closure.
2. To evaluate chronic-wound-related pain.
3. To evaluate Quality of Life.
Exploratory Objectives
1. Assess the number of chronic wound-related complications (increased wound sizes, infections, dermatitis).
2. Assess the number of clinical signs of infection in participants.
3. Determine the species of pathogenic bacteria present in wound.
Screening: up to 1 week. Treatment: TAI will take 1 day. Standard wound care will be ongoing until the wound closes, as it would in a wound care center.
Follow-up:
Once weekly (+/-1 week) for 2 weeks, followed by Biweekly (+/-1week) for 4 more weeks. There will also be a 3 month (+/- 2 weeks) and 6 month (+/- 4 weeks) follow up visits. Total duration of participant participation is up to approximately 1 year. Total duration of the study for recruitment and completion of visits is expected to be up to two years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Non-healing Wound
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
This is a single center, prospective, comparative interventional, two-arm parallel group, randomized, clinical safety and efficacy trial comparing a group receiving standard wound care with tumescent antibiotic injection (TAI) with a control group receiving standard wound care
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control Group (Standard Wound Care)
The 'control' group will receive wound care treatment in accordance to standard of care procedures. The 'control' group will not receive study intervention.
Group Type
NO_INTERVENTION
No interventions assigned to this group
Treatment Group (Tumescent Antibiotic Injection)
The 'treatment' group will receive wound care treatment in accordance to standard of care procedures along with the study intervention, a one-time tumescent antibiotic injection (TAI).
Group Type
EXPERIMENTAL
CeFAZolin Injectable Solution
Intervention Type
DRUG
One gram Cefazolin reconstituted in 100 mL 0.9% Sodium Chloride (normal saline)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CeFAZolin Injectable Solution
One gram Cefazolin reconstituted in 100 mL 0.9% Sodium Chloride (normal saline)
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Kefzol, Ancef
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female ≥18 years of age.
* Must have:
1. One or more full thickness ulcers on the lower extremity, upper extremity (excluding the hands) or trunk with a surface area exceeding 0.5 cm\^2 (50 mm\^2) and less than 30 cm\^2 (6\*5 cm) after debridement (full thickness means extending through the epidermis and dermis but not involving tendon, bone or joint capsule).
2. Presence of a chronic wound (including venous ulcer, arterial ulcer, below knee pressure ulcer, diabetic foot ulcer, ischemic ulcer) that has existed for \>4 weeks at Visit 1.
3. Documentation that the wound has been treated at least 2 times at the wound care center.
4. Documentation that the wound area has not decreased by more than 50% in 4 weeks.
5. Willing to provide written informed consent (and assent when applicable) obtained from participant or participant's legal representative and ability for participant to comply with the requirements of the study.
* Adequate perfusion as demonstrated by TcPO2≥40 mm Hg, ABI ≥ 0.7, or great toe pressure≥50 mm Hg, or palpable pulses of the lower extremity such as dorsalis pedis and/or posterior tibial artery or palpable radial artery in the upper extremity.
* In the opinion of the investigator, participants must be considered reliable, willing, and able to give signed informed consent in English and sign the informed consent form.
* For participants of reproductive potential, two of the following forms of contraception are required between visits 1-4 (total of 3-6 weeks), one of which must be a barrier method:
1. Condoms (male or female) with or without a spermicidal agent
2. Diaphragm or cervical cap with spermicide
3. Intrauterine device (IUD)
4. Tubal ligation
5. Hormone-based contraceptive such as oral birth control pills
2. Clinically severe wound at high risk for amputation as determined by the Medical Director.
3. All pressure ulcers except below knee pressure ulcers.
* Cellulitis or acute infection as determined by:
1. Significant wound erythema, induration, warmth, presence of pus, or tenderness, determined by PI or medical director ≥ 2 cm radially from wound margin.
2. Fever with electronic temp \>100.4°F (\>38°C)
* Following enrollment, if wound culture returns positive for Pseudomonas.
* Participants with symptoms of systemic infection or uncontrolled diabetes mellitus (e.g., severe hyperglycemia, ketoacidosis, azotemia).
* Participants who are allergic or have shown hypersensitivity to penicillin, cefazolin, other beta-lactams, the cephalosporin group of antibiotics, lidocaine, or to local anesthetics of the amide type.
* Participants requiring intravenous antimicrobials during the study period for any infection, including diabetic foot ulcer. Mild localized infection that would be treated on an outpatient basis could be approved by Medical Director authorization.
* Participants who are currently treated by dialysis, awaiting dialysis, or who have an estimated glomerular filtration rate of ≤ 30 mL/min/1.73 m\^2.
* Participants who are expected to be unable to care for their ulcer because of hospitalization, vacation, disability, etc., during the study period.
* Participants with known active alcohol or substance abuse within the 6 months preceding study entry.
* Participants who are receiving systemic corticosteroids (in a dose equivalent to ≥20 mg of prednisone per day), biologic therapy, immunosuppressants, , radiation therapy, or cytotoxic agents, unless approved by medical director authorization
* Participants who require treatment for a primary or metastatic malignancy (other than squamous or basal cell carcinoma of the skin, not involving the wound site).
* Participants with acquired immune deficiency syndrome (AIDS) or known human immunodeficiency virus (HIV) positivity.
* Participants with other conditions considered by the investigator to be reasons for disqualification that may jeopardize participant safety or interfere with the objectives of the trial (e.g., acute illness or exacerbation of chronic illness, lack of motivation, history of poor compliance).
* Women who are breastfeeding, pregnant, or attempting to become pregnant.
* Active acute medically unstable condition defined by:
1. Diabetes Mellitus Type 1 or 2, with A1C greater than 9.5. Consideration to HbA1c higher than 9.5 - 10.0% after consultation with the medical director or PI.
2. Unstable cardiovascular or other high-risk general medical condition making participation in the study a significant risk to the participant, per medical director determination.
3. Laboratory evidence of severe metabolic, renal, hepatic, endocrine, hematologic disorder per medical director determination.
4. Recent trauma complicated by significant bone, nerve, or vascular damage.
5. Sickle Cell Disease.
* Participant is enrolled/participating in another study or does not agree to refrain from participating in another study while enrolled in this study.
* Must have:
1. One or more full thickness ulcers on the lower extremity, upper extremity (excluding the hands) or trunk with a surface area exceeding 0.5 cm\^2 (50 mm\^2) and less than 30 cm\^2 (6\*5 cm) after debridement (full thickness means extending through the epidermis and dermis but not involving tendon, bone or joint capsule).
2. Presence of a chronic wound (including venous ulcer, arterial ulcer, below knee pressure ulcer, diabetic foot ulcer, ischemic ulcer) that has existed for \>4 weeks at Visit 1.
3. Documentation that the wound has been treated at least 2 times at the wound care center.
4. Documentation that the wound area has not decreased by more than 50% in 4 weeks.
5. Willing to provide written informed consent (and assent when applicable) obtained from participant or participant's legal representative and ability for participant to comply with the requirements of the study.
* Adequate perfusion as demonstrated by TcPO2≥40 mm Hg, ABI ≥ 0.7, or great toe pressure≥50 mm Hg, or palpable pulses of the lower extremity such as dorsalis pedis and/or posterior tibial artery or palpable radial artery in the upper extremity.
* In the opinion of the investigator, participants must be considered reliable, willing, and able to give signed informed consent in English and sign the informed consent form.
* For participants of reproductive potential, two of the following forms of contraception are required between visits 1-4 (total of 3-6 weeks), one of which must be a barrier method:
1. Condoms (male or female) with or without a spermicidal agent
2. Diaphragm or cervical cap with spermicide
3. Intrauterine device (IUD)
4. Tubal ligation
5. Hormone-based contraceptive such as oral birth control pills
2. Clinically severe wound at high risk for amputation as determined by the Medical Director.
3. All pressure ulcers except below knee pressure ulcers.
* Cellulitis or acute infection as determined by:
1. Significant wound erythema, induration, warmth, presence of pus, or tenderness, determined by PI or medical director ≥ 2 cm radially from wound margin.
2. Fever with electronic temp \>100.4°F (\>38°C)
* Following enrollment, if wound culture returns positive for Pseudomonas.
* Participants with symptoms of systemic infection or uncontrolled diabetes mellitus (e.g., severe hyperglycemia, ketoacidosis, azotemia).
* Participants who are allergic or have shown hypersensitivity to penicillin, cefazolin, other beta-lactams, the cephalosporin group of antibiotics, lidocaine, or to local anesthetics of the amide type.
* Participants requiring intravenous antimicrobials during the study period for any infection, including diabetic foot ulcer. Mild localized infection that would be treated on an outpatient basis could be approved by Medical Director authorization.
* Participants who are currently treated by dialysis, awaiting dialysis, or who have an estimated glomerular filtration rate of ≤ 30 mL/min/1.73 m\^2.
* Participants who are expected to be unable to care for their ulcer because of hospitalization, vacation, disability, etc., during the study period.
* Participants with known active alcohol or substance abuse within the 6 months preceding study entry.
* Participants who are receiving systemic corticosteroids (in a dose equivalent to ≥20 mg of prednisone per day), biologic therapy, immunosuppressants, , radiation therapy, or cytotoxic agents, unless approved by medical director authorization
* Participants who require treatment for a primary or metastatic malignancy (other than squamous or basal cell carcinoma of the skin, not involving the wound site).
* Participants with acquired immune deficiency syndrome (AIDS) or known human immunodeficiency virus (HIV) positivity.
* Participants with other conditions considered by the investigator to be reasons for disqualification that may jeopardize participant safety or interfere with the objectives of the trial (e.g., acute illness or exacerbation of chronic illness, lack of motivation, history of poor compliance).
* Women who are breastfeeding, pregnant, or attempting to become pregnant.
* Active acute medically unstable condition defined by:
1. Diabetes Mellitus Type 1 or 2, with A1C greater than 9.5. Consideration to HbA1c higher than 9.5 - 10.0% after consultation with the medical director or PI.
2. Unstable cardiovascular or other high-risk general medical condition making participation in the study a significant risk to the participant, per medical director determination.
3. Laboratory evidence of severe metabolic, renal, hepatic, endocrine, hematologic disorder per medical director determination.
4. Recent trauma complicated by significant bone, nerve, or vascular damage.
5. Sickle Cell Disease.
* Participant is enrolled/participating in another study or does not agree to refrain from participating in another study while enrolled in this study.
Exclusion Criteria
* Participants with limb threatening infection, extensive cellulitis (≥2 cm radially beyond the borders of the wound), lymphangitis, fasciitis, deep tissue infection, abscess, pus, osteomyelitis, or other evidence of local or systemic complications of infection.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, Los Angeles
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Seth J Putterman
Professor of Physics and Astronomy at University of California, Los Angeles
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Seth Putterman, PhD
Role: STUDY_DIRECTOR
University of California, Los Angeles
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, Los Angeles
Los Angeles, California, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Armstrong DG, Boulton AJM, Bus SA. Diabetic Foot Ulcers and Their Recurrence. N Engl J Med. 2017 Jun 15;376(24):2367-2375. doi: 10.1056/NEJMra1615439. No abstract available.
Reference Type
BACKGROUND
O'Meara S, Cullum N, Nelson EA, Dumville JC. Compression for venous leg ulcers. Cochrane Database Syst Rev. 2012 Nov 14;11(11):CD000265. doi: 10.1002/14651858.CD000265.pub3.
Reference Type
BACKGROUND
Krzyszczyk P, Schloss R, Palmer A, Berthiaume F. The Role of Macrophages in Acute and Chronic Wound Healing and Interventions to Promote Pro-wound Healing Phenotypes. Front Physiol. 2018 May 1;9:419. doi: 10.3389/fphys.2018.00419. eCollection 2018.
Reference Type
BACKGROUND
Sen CK, Gordillo GM, Roy S, Kirsner R, Lambert L, Hunt TK, Gottrup F, Gurtner GC, Longaker MT. Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen. 2009 Nov-Dec;17(6):763-71. doi: 10.1111/j.1524-475X.2009.00543.x.
Reference Type
BACKGROUND
Nussbaum SR, Carter MJ, Fife CE, DaVanzo J, Haught R, Nusgart M, Cartwright D. An Economic Evaluation of the Impact, Cost, and Medicare Policy Implications of Chronic Nonhealing Wounds. Value Health. 2018 Jan;21(1):27-32. doi: 10.1016/j.jval.2017.07.007. Epub 2017 Sep 19.
Reference Type
BACKGROUND
Barshes NR, Sigireddi M, Wrobel JS, Mahankali A, Robbins JM, Kougias P, Armstrong DG. The system of care for the diabetic foot: objectives, outcomes, and opportunities. Diabet Foot Ankle. 2013 Oct 10;4. doi: 10.3402/dfa.v4i0.21847.
Reference Type
BACKGROUND
Koulakis JP, Rouch J, Huynh N, Wu HH, Dunn JCY, Putterman S. Tumescent Injections in Subcutaneous Pig Tissue Disperse Fluids Volumetrically and Maintain Elevated Local Concentrations of Additives for Several Hours, Suggesting a Treatment for Drug Resistant Wounds. Pharm Res. 2020 Feb 10;37(3):51. doi: 10.1007/s11095-020-2769-2.
Reference Type
BACKGROUND
Nicolau DP, Silberg BN. Cefazolin potency against methicillin-resistant Staphylococcus aureus: a microbiologic assessment in support of a novel drug delivery system for skin and skin structure infections. Infect Drug Resist. 2017 Jul 26;10:227-230. doi: 10.2147/IDR.S134497. eCollection 2017.
Reference Type
BACKGROUND
Okuma K, Iwakawa K, Turnidge JD, Grubb WB, Bell JM, O'Brien FG, Coombs GW, Pearman JW, Tenover FC, Kapi M, Tiensasitorn C, Ito T, Hiramatsu K. Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J Clin Microbiol. 2002 Nov;40(11):4289-94. doi: 10.1128/JCM.40.11.4289-4294.2002.
Reference Type
BACKGROUND
Durand BARN, Pouget C, Magnan C, Molle V, Lavigne JP, Dunyach-Remy C. Bacterial Interactions in the Context of Chronic Wound Biofilm: A Review. Microorganisms. 2022 Jul 25;10(8):1500. doi: 10.3390/microorganisms10081500.
Reference Type
BACKGROUND
Kim H, Park H, Lee SJ. Effective method for drug injection into subcutaneous tissue. Sci Rep. 2017 Aug 29;7(1):9613. doi: 10.1038/s41598-017-10110-w.
Reference Type
BACKGROUND
Scali C, Kunimoto B. An update on chronic wounds and the role of biofilms. J Cutan Med Surg. 2013 Nov-Dec;17(6):371-6. doi: 10.2310/7750.2013.12129.
Reference Type
BACKGROUND
Boeni R. Safety of tumescent liposuction under local anesthesia in a series of 4,380 patients. Dermatology. 2011;222(3):278-81. doi: 10.1159/000327375. Epub 2011 May 24.
Reference Type
BACKGROUND
Harb G, Lebel F, Battikha J, Thackara JW. Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers. Curr Med Res Opin. 2010 Feb;26(2):279-88. doi: 10.1185/03007990903432900.
Reference Type
BACKGROUND
Coerper S, Beckert S, Kuper MA, Jekov M, Konigsrainer A. Fifty percent area reduction after 4 weeks of treatment is a reliable indicator for healing--analysis of a single-center cohort of 704 diabetic patients. J Diabetes Complications. 2009 Jan-Feb;23(1):49-53. doi: 10.1016/j.jdiacomp.2008.02.001. Epub 2008 Apr 3.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
https://www.uclahealth.org/locations/ucla-center-wound-healing-limb-preservation
UCLA Center for Wound Healing \& Limb Preservation
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB#23-001248
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Study of the Efficacy of Sharp Debridement for the Management of Chronic Wounds
NCT00990522
WITHDRAWN
NA
Treatment of Chronic Leg Ulcers With Autologous Stromal Vascular Fraction
NCT02987101
UNKNOWN
NA
Clinical Implications of Biofilm in Chronic Wound
NCT05054244
UNKNOWN
UC-MSCs Gel Treatment Difficult Healing of Skin Ulcers
NCT02685722
COMPLETED
PHASE1
Treatment of Chronic Wounds With Cold Plasma -Plasma Care® vs. Placebo
NCT07050667
COMPLETED
NA
Evaluation of Cold Plasma in Chronic Wound Healing
NCT06964048
NOT_YET_RECRUITING
NA
Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers
NCT05608187
TERMINATED
PHASE2
The Difference in Wound Size Reduction Comparing Two Frequently Used Wound Dressings in Everyday Care
NCT03596112
COMPLETED
NA
Phase 2 Randomized Study to Compare Ultrasonic Drug Delivery to Standard of Care for the Treatment of Infections in Non-Healing Wounds
NCT03732365
UNKNOWN
PHASE2
Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion
NCT01238276
NO_LONGER_AVAILABLE
Evaluation of Topical Wound Oxygen (two2) Therapy
NCT00871312
TERMINATED
NA
Adipose Derived Regenerative Cellular Therapy of Chronic Wounds
NCT02092870
COMPLETED
PHASE2
ChitoCare Medical Wound Healing Gel PMCF Study on Healing of Chronic Wounds
NCT05570877
COMPLETED
NA
A Prospective, Multi Centre, Interventional, Non-comparator, Open Label Study to Demonstrate the Efficacy, Safety, and Performance of ConvaFoam™ Dressings in the Management of Indicated Chronic Wound Types.
NCT05632250
COMPLETED
NA
A Study to Evaluate Microvessel Ultrasound Imaging of Wound Healing in Patients With Chronic Ulcers
NCT05739149
RECRUITING
NA
Clinical Trial To Study The Anti-scarring Effect Of Cicatricell
NCT03020420
COMPLETED
NA
Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing
NCT01214811
COMPLETED
PHASE3
Therapeutic Potential of Stem Cell Conditioned Medium on Chronic Ulcer Wounds
NCT04134676
COMPLETED
PHASE1
Pathophysiology of Chronic Wounds
NCT00006437
COMPLETED
A Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers
NCT00069446
COMPLETED
PHASE1
Ultrasonic Wound Debridement vs. Standard Sharp Debridement
NCT01237392
COMPLETED
NA
Diabetic Foot Ulcer Study Comparing Cytal Wound Matrix 1-Layer to Standard of Care
NCT03626623
TERMINATED
NA
Cold atmOspheric plaSMa Therapy Versus standArd Wound Care in Diabetic Foot and Venous Leg ulcerS
NCT07251426
NOT_YET_RECRUITING
NA
Efficacy of RPh201 Applied Topically for the Treatment of Hard to Heal Chronic Ulcerated Wounds
NCT01429519
TERMINATED
PHASE1/PHASE2
Next Science Wound Gel Efficacy in Chronic Wound Versus Standard of Care
NCT02138994
COMPLETED
NA